"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...

A man died after being repeatedly kicked by two drug dealers outside his Birmingham home, a murder trial has heard. Craig ...

A sweeping bill would fund the VA to examine ketamine, magic mushrooms and other hallucinogens for potential medical use for ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

The experimental treatment, called IB409, aims to protect the heart and brain during heart attacks and strokes by preventing ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Forbes contributors publish independent expert analyses and insights. Tor Constantino is an ex-reporter, turned AI consultant & tech writer. The cost to create an innovative drug within the U.S.

A stylized image of Max Barnhart sitting on a chair with his arm on a pillow, receiving an IV infusion. The background is a grid containing a microscope image of malaria parasites flanked on each side ...